{
    "nctId": "NCT00227656",
    "briefTitle": "Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer",
    "officialTitle": "Phase II Trial of Capecitabine (Xeloda\u00ae) and Pegylated Interferon Alfa-2A(Pegasys\u00ae) for Recurrent or Progressive Brain Metastasis From Breast Carcinoma",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Neurologic progression-free survival rate at 6 months",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer that metastasized to the brain, meeting all of the following criteria:\n\n  * Must have \u2265 1 inoperable brain metastases, meeting 1 of the following criteria:\n\n    * Progressive or recurrent disease after prior whole-brain or stereotactic radiotherapy\n    * Ineligible for OR unwilling to be treated with radiotherapy\n  * At least 1 unidimensionally measurable brain metastasis by enhanced MRI within the past 21 days\n  * No progression or development of central nervous system (CNS) metastasis during prior treatment with capecitabine, fluorouracil, interferon alfa, or interferon beta\n* Systemic (i.e., outside the CNS system) cancer must be stable\n\n  * No progressive disease (e.g., liver, lymphangitic, or lung metastases)\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Karnofsky 70-100%\n\nLife expectancy\n\n* More than 12 weeks\n\nHematopoietic\n\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 10 mg/dL\n* No history of idiopathic thrombocytopenic purpura\n* No known uncontrolled coagulopathy\n* No increased risk for anemia (e.g., thalassemia or spherocytosis)\n* No medically problematic anemia\n\nHepatic\n\n* aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \u2264 2.5 times upper limit of normal (ULN) (5 times ULN for patients with concurrent liver metastases )\n* Bilirubin \u2264 1.5 times ULN\n* Alkaline phosphatase \u2264 2.5 times ULN (5 times ULN for patients with concurrent liver metastases; 10 times ULN for patients with concurrent bone metastases)\n\nRenal\n\n* Creatinine \u2264 1.5 times ULN OR\n* Creatinine clearance \u2265 30 mL/min\n\nCardiovascular\n\n* No congestive heart failure\n* No symptomatic coronary artery disease\n* No medically uncontrolled arrhythmia\n* No other clinically significant cardiac disease\n* No myocardial infarction within the past 12 months\n\nGastrointestinal\n\n* No history of inflammatory bowel disease\n* Must have intact upper gastrointestinal tract\n* Able to swallow tablets\n* No malabsorption syndrome\n* No history of gastrointestinal bleeding\n\nImmunologic\n\n* No prior unanticipated severe reaction to fluoropyrimidine therapy, interferon, pegylated interferon, or a pegylated moiety\n* No known sensitivity to fluorouracil\n* No serious uncontrolled infection\n* No history of immunologically mediated disease\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 6 months after completion of study treatment\n* No known dihydropyrimidine dehydrogenase deficiency\n* No history of depression characterized by a suicide attempt\n* No history of hospitalization for psychiatric disease\n* No history of other severe psychiatric disease\n* No prior disability as a result of psychiatric disease\n* No history of clinically significant psychiatric disability that would preclude study compliance\n* No other malignancy within the past 5 years except cured nonmelanoma skin cancer or treated carcinoma in situ of the cervix\n* No uncontrolled thyroid dysfunction (e.g., thyroid-stimulating hormone not in normal range)\n* No evidence of severe retinopathy (e.g., Cytomegalovirus (CMV) retinitis or macular degeneration)\n* No clinically relevant ophthalmologic disorders due to diabetes or hypertension\n* No other serious uncontrolled medical conditions that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* See Disease Characteristics\n* At least 3 months since prior interferon alfa or interferon beta\n\nChemotherapy\n\n* See Disease Characteristics\n* At least 3 months since prior capecitabine or fluorouracil\n\nEndocrine therapy\n\n* Concurrent hormonal agents (e.g., tamoxifen, raloxifene, or anastrazole) for breast cancer allowed\n\nRadiotherapy\n\n* See Disease Characteristics\n\nSurgery\n\n* More than 4 weeks since prior major surgery and recovered\n\nOther\n\n* More than 4 weeks since prior participation in another investigational drug study\n* At least 4 weeks since prior and no concurrent brivudine or sorivudine\n* No concurrent cimetidine\n* No other concurrent investigational or commercial agents or therapies for this malignancy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}